A groundbreaking article in Pharmacological Research outlines the promises of upcoming pharmacological therapies designed to target systemic inflammation, with the potential to revolutionize the prevention of cardiovascular diseases (CVD). The extensive review, led by a team of Spanish researchers from the Institute of Health Research INCLIVA and the University of Valencia, takes a critical look at how current and in-development drugs not only treat metabolic disorders but also mitigate their cardiovascular implications.

DOI: 10.1016/j.phrs.2024.107058

A Nexus Between Metabolic Disorders and CVD

Cardiovascular disease, a perpetual frontrunner in the global mortality rates, is intricately linked to metabolic abnormalities such as hypercholesterolemia and obesity. These disorders induce aortic inflammation, seeding the growth of atherosclerosis—essentially the root of most cardiovascular calamities. The Spanish scholars, through meticulous analysis, underscore the association between these disorders and the endothelium’s shift toward a proinflammatory and prothrombotic state, expediting arterial wall damage.

The Inflammatory Culprit in Endothelial Dysfunction

Systemic inflammation, the subtle infiltrator in metabolic disorders, has been definitively correlated with endothelial dysfunction, a known precursor to atherosclerotic disease. The research team, consisting of Domingo Elena E, Marques Patrice P, Francisco Vera V, Piqueras Laura L, and Sanz Maria-Jesus MJ, exhumes insights into the hows and whys of immune cells congregating within our vascular walls, an event that unofficially kicks off atherogenesis.

Pharmacol Res. 2024; S1043-6618(24)00002-1

From Theory to Therapy – The Pharmacological Frontline

On the pharmaceutical battlefield, several strategies are deployed to combat these metabolic disorders. The researchers scrutinize established, emerging, and pipeline drugs for their potency in pacifying this systemic inflammatory fervor. Their article paints a hopeful portrait of these therapies’ abilities to alter the cardiovascular misfortunes traditionally tethered to metabolic issues.

The Future of Cardiovascular Disease Prevention

With their study, the INCLIVA team not only maps out the complexities of metabolic-induced inflammation but also propels a call-to-action for approaching CVD prevention from an anti-inflammatory angle. As they parse through the molecular intricacies of the disease process, they spotlight the transformative impact of therapies that double as both metabolic correctives and cardiovascular shields.

A Pledge for Comprehensive Care

By signifying inflammation as a shared enemy of vascular and metabolic well-being, the authors nudge the medical community toward a holistic treatment ideology—one that doesn’t merely silence symptomatic tumult but that stabilizes the systemic disorder driving the pathology.


1. Elena E, D., Patrice P, M., Vera V, F., Laura L, P., & Maria-Jesus MJ, S. (2024). Targeting systemic inflammation in metabolic disorders: A therapeutic candidate for the prevention of cardiovascular diseases? Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107058

2. Libby, P., Ridker, P. M., Hansson, G. K. (2011). Inflammation in Atherosclerosis: From Pathophysiology to Practice. Journal of the American College of Cardiology, 54(23), 2129–2138. https://doi.org/10.1016/j.jacc.2009.09.009

3. Osborn, O., Olefsky, J. M. (2012). The cellular and signaling networks linking the immune system and metabolism in disease. Nature Medicine, 18(3), 363–374. https://doi.org/10.1038/nm.2627

4. Hotamisligil, G. S. (2017). Foundations of Immunometabolism and Implications for Metabolic Health and Disease. Immunity, 47(3), 406–420. https://doi.org/10.1016/j.immuni.2017.08.009

5. Goldfine, A. B., Fonseca, V., Jablonski, K. A., Pyle, L., Staten, M. A., Shoelson, S. E.; TINSAL-T2D (Targeting Inflammation using Salsalate in Type 2 Diabetes) Study Team. (2010). The Effects of Salsalate on Glycemic Control in Patients with Type 2 Diabetes: A Randomized Trial. Annals of Internal Medicine, 152(6), 346–357. https://doi.org/10.7326/0003-4819-152-6-201003160-00004


1. Cardiovascular Disease Prevention
2. Anti-inflammatory Therapy
3. Metabolic Disorders Treatment
4. Endothelial Dysfunction
5. Lipid-Lowering Pharmacology

Declaration of Interest
As per the article documentation, no potential conflicts of interest relevant to this piece were reported.

As healthcare steers toward a new epoch wherein systemic inflammation garners the spotlight as a smoldering threat to cardiovascular sanctity, it is the synthesis of insights like those offered by the INCLIVA team that will pave the path to not just managing, but mastering, the metabolic origins of our heart’s adversaries. With their compelling treatise on the subject, the realms of pharmacology, cardiology, and endocrinology coalesce under a unified front, vigilantly guarding the lifelines of millions across the globe.